Captor Therapeutics SA
WSE:CTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (24.1), the stock would be worth zł48.3 (39% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 39.5 | zł79.2 |
0%
|
| 3-Year Average | 24.1 | zł48.3 |
-39%
|
| 5-Year Average | 40.7 | zł81.6 |
+3%
|
| Industry Average | 2 | zł4.03 |
-95%
|
| Country Average | 1.1 | zł2.28 |
-97%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
zł451.2m
|
/ |
Jul 2025
zł11.1m
|
= |
|
|
zł451.2m
|
/ |
Dec 2025
zł7.6m
|
= |
|
|
zł451.2m
|
/ |
Dec 2026
zł57.1m
|
= |
|
|
zł451.2m
|
/ |
Dec 2027
zł21.9m
|
= |
|
|
zł451.2m
|
/ |
Dec 2028
zł36.8m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| PL |
C
|
Captor Therapeutics SA
WSE:CTX
|
438m PLN | 39.5 | -11.2 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
292.6B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 351.6 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
100.8B ZAR | 5.6 | 10.4 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
67.3B USD | 0 | 38 034.1 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
53B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
37.1B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
31.4B EUR | 1.1 | 175.7 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
34.4B USD | 14.4 | -3 171.8 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
29.6B ZAR | 5.6 | 6.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.6 |
| Median | 1.1 |
| 70th Percentile | 2.7 |
| Max | 643.7 |
Other Multiples
Captor Therapeutics SA
Glance View
Captor Therapeutics SA engages in the development of protein degradation drugs for cancer and autoimmune diseases. The company is headquartered in Wroclaw, Woj. Dolnoslaskie and currently employs 98 full-time employees. The company went IPO on 2021-04-19. The firm works in the field of neoplastic and autoimmune diseases for which there is no treatment option, or the available methods show therapeutic limitations. The firm covers aspects of early-stage drug development to deliver therapeutics for life-threatening and life-impairing diseases. The broadly applicable Optigrade tm Targeted Protein Degradation (TPD) platform allows for the creation of new drugs.
